James Callaway
Direttore/Membro del Consiglio presso XENETIC BIOSCIENCES, INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Dr. James E.
Callaway is an Independent Director at Kalgene Pharmaceuticals, Inc., an Independent Non-Executive Director at Xenetic Biosciences, Inc. and an Independent Director at NURAVAX, INC.
He is on the Board of Directors at Kalgene Pharmaceuticals, Inc., Xenetic Biosciences, Inc. and NURAVAX, INC.
Dr. Callaway was previously employed as a President & Chief Executive Officer by ArmaGen Technologies, Inc., a President & Chief Executive Officer by Cebix, Inc., a Corporate Strategy Consultant by Callaway Innovations, and a Head-Development by Elan Pharmaceuticals LLC.
He received his doctorate degree from the University of California.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di James Callaway
Società | Posizione | Inizio |
---|---|---|
XENETIC BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 14/08/2017 |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Direttore/Membro del Consiglio | 01/04/2020 |
NURAVAX, INC.
NURAVAX, INC. Miscellaneous Commercial ServicesCommercial Services The American company specializes in immunotherapy for neurodegenerative disorders. Nuravax aims to create a new segment in the market for the preventive treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) by developing safe and highly immunogenic preventive vaccines for preclinical PD/DLB and AD people based on a set of novel non-invasive and accurate disease biomarkers. The private company estimates the size of this market as approximately 40 million preclinical AD people at risk of disease. Nuravax is licensed for the patented multitep platform technology for the commercialization of prophylactic vaccines against all neurodegenerative disorders. The company is responsible for implementing co-development and sub-licensing agreements with larger biotech and pharmaceutical companies, and for further clinical validation of products. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di James Callaway
Società | Posizione | Fine |
---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Amministratore Delegato | 01/01/2016 |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Amministratore Delegato | 01/01/2012 |
Callaway Innovations | Corporate Officer/Principal | - |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Formazione di James Callaway
University of California | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
XENETIC BIOSCIENCES, INC. | Health Technology |
Aziende private | 6 |
---|---|
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Health Services |
NURAVAX, INC.
NURAVAX, INC. Miscellaneous Commercial ServicesCommercial Services The American company specializes in immunotherapy for neurodegenerative disorders. Nuravax aims to create a new segment in the market for the preventive treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) by developing safe and highly immunogenic preventive vaccines for preclinical PD/DLB and AD people based on a set of novel non-invasive and accurate disease biomarkers. The private company estimates the size of this market as approximately 40 million preclinical AD people at risk of disease. Nuravax is licensed for the patented multitep platform technology for the commercialization of prophylactic vaccines against all neurodegenerative disorders. The company is responsible for implementing co-development and sub-licensing agreements with larger biotech and pharmaceutical companies, and for further clinical validation of products. | Commercial Services |
Callaway Innovations |
- Borsa valori
- Insiders
- James Callaway